Overview
Imaging supports delivery planning monitoring engraftment and assessing functional outcomes in regenerative medicine and cell therapies. Modalities include MRI PET and ultrasound with specialized tracers or labeling techniques. Quantitative imaging provides non invasive biomarkers of therapy distribution and effect.
Labeling and Tracers
Cell labeling with iron nanoparticles PET reporter genes and targeted tracers enable visualization of cell location and viability. Each labeling approach has trade offs in sensitivity specificity and potential biological effects. Validation includes correlation with histology and functional outcomes in preclinical and early clinical studies.
Functional Assessment
Imaging assesses tissue perfusion inflammation and functional recovery using perfusion MRI PET metabolic imaging and elastography. Longitudinal imaging tracks durability of response and potential adverse effects such as ectopic tissue growth. Standardized protocols support comparability across trials and centers.
Clinical Integration
Imaging informs patient selection delivery technique and timing of adjunctive therapies and supports safety monitoring. Multidisciplinary teams including imaging scientists clinicians and regulatory experts are essential for trial design. Imaging endpoints may accelerate development by providing early signals of efficacy and safety.